Scaling AI's Promise in Healthcare: The Time Is Now
ZS CEO Pratap Khedkar warns pharma must move from isolated AI pilots to scalable, high‑impact use cases such as clinical trials, commercialization, and supply‑chain intelligence. He cites a new ZS‑Healthcare Leadership Council report showing the sector is transitioning toward targeted applications. Scaling hinges on resolving fragmented regulatory frameworks and a growing trust gap among patients and providers. Khedkar envisions personalization at scale and an end‑to‑end data ecosystem as the future of AI‑driven patient impact.
Will We Repeat a Deadly Mistake From 100 Years Ago?
A century ago the U.S. government rejected warnings about leaded gasoline, allowing its use for five decades and causing widespread lead poisoning. The resulting health crisis lowered children’s IQ, caused millions of premature deaths, and cost hundreds of billions of...
The CDC Was Ordered to Prove the DTaP Vaccine Didn't Cause Autism... But Their Only Study Showed It Did
The Institute of Medicine (IOM) concluded in 1991 that evidence was insufficient to determine whether the pertussis (DTaP) vaccine causes autism, a finding reiterated by a 2012 CDC/HRSA review. The only study suggesting a link was excluded for lacking an...
The $1.8B Ozempic Middleman and What It Actually Means for Health Tech
Medvi, a two‑person GLP‑1 telehealth brand, posted $401 million in 2025 revenue and is on track for $1.8 billion in 2026, delivering a 16.2% net margin. The company built its consumer‑facing platform using AI tools for under $20,000, while outsourcing all clinical...
Proposing Atrial Fibrillation and Heart Failure to Be Manifestations of the Same Condition
Researchers propose that atrial fibrillation and heart failure share a common molecular origin: reduced expression of the transcription factor TBX5. Mouse models lacking TBX5 in the atria develop arrhythmias and gene‑expression patterns that closely resemble heart‑failure signatures. Human atrial tissue...
Headline Vs. Study, Economics Edition
A JAMA research letter examined the CMS BALANCE model, estimating that treating 550,000 to 3.6 million Medicare beneficiaries with semaglutide could generate savings sufficient to offset program costs. The study presented a range of possible budget outcomes and concluded that additional...
Why ‘Boring’ AI Could Save Healthcare When the Bubble Bursts
The healthcare AI market is facing a sharp correction, with Series B funding dropping 84% from its 2021 peak and 95% of enterprise pilots failing to show ROI. Most failures stem from demo‑centric tools that cannot survive fragmented clinical data environments....
Researchers Develop Nasally Delivered DNA Vaccine for Tuberculosis
Johns Hopkins researchers have created an intranasal DNA vaccine that fuses the relMtb and Mip3α genes to target drug‑tolerant tuberculosis persisters. In mouse models the vaccine accelerated bacterial clearance, lowered lung inflammation and prevented relapse when combined with standard therapy....
Innate Pharma to Participate in the Kempen Life Sciences Conference
Innate Pharma announced that senior executives will hold one‑on‑one investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 15‑16, 2026. The biotech firm will use the event to showcase its pipeline, including the Nectin‑4 ADC IPH4502, the...
PTSD Is Almost Incurable. Psychedelics Can Help — but only in Three U.S. States and Australia
Australia has opened a regulated pathway for MDMA‑assisted psychotherapy to treat post‑traumatic stress disorder, making it one of the few countries where the drug can be used medically. Early data from Dr. Ranil Gunewardene’s practice show more than 50 % of...
How Robert F. Kennedy Jr.’s Vaccine Agenda Risks a Resurgence of Deadly Childhood Plagues
Robert F. Kennedy Jr., now Secretary of Health and Human Services, is steering U.S. vaccine policy toward skepticism, threatening the two pillars that have protected children for decades: parental trust and reliable access. He is considering regulatory changes that could...
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. Difficile Infection Will Continue...
Vedanta Biosciences announced that the independent Data Monitoring Committee has completed the first prespecified interim analysis of its Phase 3 RESTORATiVE303 trial and recommended the study continue unchanged. The interim data showed efficacy surpassing the futility threshold with no new safety...
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
Pulse Biosciences (Nasdaq: PLSE) will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026, at 9:30 am ET. The company will showcase its proprietary nPulse™ platform, which uses nanosecond pulsed field ablation (nsPFA™) to treat atrial fibrillation and...
SV Health Investors Acquires EpiVax
SV Health Investors (SVHI) announced the acquisition of EpiVax, a Providence‑based bioanalytical CRO that specializes in immunogenicity risk assessments for pharma and biotech firms. The deal adds a proven scientific platform, including the ISPRI predictive software and cell‑based assays, to...
Why Leaving Hospital Medicine for Private Practice Was Worth the Risk
Dr. Shiv K. Goel left his role as medical director at a San Antonio hospital to launch Prime Vitality, a functional, integrative practice. He faced steep financial pressures, overhead worries, and professional isolation during the first year. A breakthrough patient...
Boston University to Apply Machine Learning to Alzheimer’s Biomarker and Cognitive Data
Boston University, leading the AI for Alzheimer’s Disease (AI4AD) consortium, is coordinating 11 research institutes to apply machine learning to massive genomic, biomarker and cognitive datasets. The team is building the PreSiBO database, which tags predictor, signature, biomarker and outcome...
President Trump Imposes 100% Tariffs on Branded Pharmaceuticals
President Trump has announced 100% tariffs on patented pharmaceutical products that lack a Most‑Favored Nation (MFN) agreement with his administration. The tariffs will take effect in 120 days for large firms and 180 days for smaller ones, while imports from...
What the Leaked Claude Code Codebase Tells Healthcare Builders About Designing Agentic Health Tech
On March 31, 2026 a 59.8 MB source‑map file unintentionally exposed Anthropic’s Claude Code TypeScript codebase, revealing roughly 512,000 lines of production‑grade AI agent logic. The leak showcases a three‑layer skeptical memory system, a coordinator mode for multi‑agent orchestration, the AutoDream consolidation...
Pharmaceutical Giant Pfizer Forced To Shut Down Updated COVID Vaccine Trials
Pfizer announced it is halting development of its updated COVID‑19 vaccine candidates, ending ongoing Phase 2/3 trials that targeted newer variants. The decision follows mixed efficacy data and waning commercial demand as the pandemic recedes. Pfizer will redirect resources toward...
Pharma and Biotech Layoffs 2026 Watch
Pharma and biotech companies continued extensive workforce reductions in early 2026, with Takeda alone eliminating 634 U.S. positions as part of a $1.2 billion annual savings plan, while Amgen, GSK, and Merck KGaA also announced cuts ranging from dozens to several...
Pharmaceutical Executive Daily: Leadership Turnover Under Trump Administration
Leadership turnover continues across major federal health agencies under the Trump administration, creating uncertainty around drug‑approval timelines, pricing policies, and public‑health initiatives. Shionogi announced a roughly $2 billion deal to acquire worldwide rights to Radicava, bolstering its neurology portfolio and gaining...
Trump Says Federal Government Can’t Fund Medicare as Iran War Costs Mount
President Donald Trump told a White House Easter audience that the federal government cannot continue funding Medicare, Medicaid, or daycare because escalating military costs from the Iran war are draining the budget. He suggested that states should assume responsibility for...
Scaling Security and Speed in Pharmaceutical Cold Chain Delivery at the Last Mile
Consumer expectations have shifted to hour‑level delivery, prompting big‑box retailers to add pharmaceutical cold‑chain shipments to their last‑mile services. This introduces stringent temperature, security, and compliance requirements that differ sharply from general‑merchandise fulfillment. Companies must blend rapid order processing with...
How the US Christian Right and Anti-Abortion Lobbyists Are Reshaping NHS Policy
An investigation by the Good Law Project revealed that Health Secretary Wes Streeting halted the NHS puberty‑blocker trial in February 2026 after receiving a letter from Professor Jacob George, who was later removed for anti‑trans bias. The correspondence was tied...
Accelerating Drug Discovery with “Paradigm Shifting” AI Model
A multi‑institution team led by Michigan State University unveiled GPS, a machine‑learning platform that predicts how a compound will alter gene expression from its chemical structure. Trained on millions of transcriptomic measurements across more than 70 cell lines, GPS screened...
Pfizer Halts COVID Shot Trial Because They Can’t Find Enough Test Subjects Willing to Take Another Booster Shot
Pfizer and BioNTech have halted a large U.S. clinical trial of an updated COVID‑19 booster after failing to enroll enough healthy adults aged 50‑64. The study required tens of thousands of participants, but recruitment stalled amid a sharp decline in...
Asundexian
Bayer’s oral factor XIa inhibitor asundexian (BAY 2433334) has delivered positive Phase 3 data in the OCEANIC‑STROKE trial, positioning it as a potential first‑in‑class therapy for secondary stroke prevention. The drug aims to block pathological clot formation while minimizing the bleeding complications common...
Shionogi Enters $2.5 Billion Agreement to Acquire All Rights to Radicava
Shionogi completed a $2.5 billion acquisition of global rights to Radicava from Tanabe Pharma, adding an approved ALS treatment to its portfolio. The deal transfers all intellectual property, sales rights and the existing commercial team, delivering an estimated $700 million in annual...
Women More Likely to Die From Cardiac Arrest because of Their Bras
Research by Thames Valley Air Ambulance and St John Ambulance shows that one in three women in the UK who suffer out‑of‑hospital cardiac arrest receive no CPR before emergency crews arrive. About 33% of men report hesitancy to perform chest compressions...
Why You Might Want to Hire Home Health Aides Through an Agency – Despite the Cost
Hiring home health aides through an agency costs more than direct hiring, but offers structured recruitment, wage transparency, and employee benefits. First Light Home Care in suburban Boston screens hundreds of candidates and hires only about 3%, paying caregivers $19‑$24...
The New Antitrust Era: Why CVS-Style Healthcare Integration Is Now the FTC’s Primary Target
The FTC and DOJ are overhauling antitrust review in healthcare, shifting focus from traditional market‑share and price analysis to how vertically integrated systems control patient flow. Updated Hart‑Scott‑Rodino filing rules now demand explanations of ecosystem design, strategic intent, and internal...
I Double and Triple and Quadruple Down, because I Know What Victory Looks Like; Meet the “Journalists”
The blog post stages a fictional, off‑the‑record interview with a figure named Kennedy, who claims to be coordinating a campaign to erode confidence in vaccines and medical regulators. The dialogue suggests a long‑term strategy to “soften up” opposition, manipulate public...
Epic’s New Networks
Epic quietly announced two network‑based products that extend its electronic health record platform beyond traditional modules like Agent Factory or Penny. The new offerings focus on creating a shared data exchange layer, positioning Epic as a hub for interoperable health...
1390. Your Doctor Is Wrong About Autism (Here’s How To Reverse It)
In the latest episode of The Human Upgrade, host Dave Asprey and integrative‑health practitioner Tracy Slepcevic argue that autism is a reversible biological condition driven by gut dysfunction, mitochondrial collapse, and toxic environmental exposures. They detail protocols—including gut healing, plasmalogen...
Closing the Gaps in Stroke Care: Access, Innovation and Global Equity
Linnea Burman, President of Medtronic Neurovascular, highlighted that nearly 12 million people suffer a stroke each year and one in four die within a year, underscoring persistent global gaps in prevention, access, and long‑term care. She emphasized that rapid treatment is...
Pharma Pulse: Foundayo’s FDA Approval and the Strategic Risk of Pharmacy Data Consolidation
Eli Lilly’s Foundayo became the first new molecular entity approved under the FDA’s National Priority Voucher pilot, clearing in a record 50 days. It is the only GLP‑1 weight‑loss pill that can be taken without food or water restrictions, aiming to...
What Will Approval of Foundayo GLP-1 Tablets Bring?
The FDA has approved Foundayo (orforglipron), the first non‑peptide oral GLP‑1 tablet for obesity. As a small‑molecule drug, it sidesteps the manufacturing complexities that plagued peptide injectables like semaglutide and tirzepatide. Daily oral dosing promises easier adherence compared with weekly...
Humanitarian Medicine Under Fire: Relief Organizations Serving Wounded Civilians in Gaza and Lebanon
The relentless bombing campaigns in Gaza and southern Lebanon since 2023 have devastated health infrastructure, leaving hospitals overwhelmed and civilian populations without basic medical care. International responders—Médecins Sans Frontières, the International Committee of the Red Cross and its Red Crescent...
Live Not By Lies
Dr. McFillin’s post draws on Solzhenitsyn’s 1974 essay “Live Not By Lies” to argue that the modern mental‑health industry thrives on collective deception. He identifies two core falsehoods: that psychiatric disorders are brain diseases and that DSM diagnoses are medical...
Doctors and Consumers in America Agree: Health Care Access and Affordability Rank Top of Mind in March 2026 (Surveys From...
Two March 2026 surveys—Athenahealth’s Physician Sentiment Survey and Gallup’s consumer poll—show health‑care access and affordability now top the concerns of both doctors and the public. Physician worry about affordable care rose to 52 % in 2026, overtaking documentation burdens, while 61 %...
Aspirin for Your Heart? Decongestants? Here Are 5 Popular Medications that You Should Avoid
The Washington Post article highlights five everyday medications that recent research suggests should be reconsidered or discarded. Low‑dose aspirin no longer offers net benefit for primary heart‑disease prevention due to bleeding risks. Phenylephrine, a common decongestant, performs no better than...
NDIS Swells the Ranks of the Public Service
The National Disability Insurance Scheme, a $50 billion Australian program (≈US$33 billion), is acting as a catalyst for employment, especially in health and social assistance sectors. Since 2020, Australian healthcare jobs have diverged from trends in other English‑speaking economies, expanding rapidly. The...
NEJM: Multistate Infant Botulism Outbreak Associated with Powdered Infant Formula
A multistate outbreak of infant botulism has been traced to ByHeart powdered infant formula, with 51 suspected or confirmed cases reported across 19 states as of December 10, 2025. Laboratory testing identified Clostridium botulinum type A in opened formula containers and matched isolates...
The Pediatric Home Health System Is Failing Children with Cancer
A landmark trial showed blinatumomab adds 10% survival for childhood acute lymphoblastic leukemia, yet most children cannot receive it at home. Roughly 70% lack access to pediatric home‑health services because reimbursement is low, nurses are scarce, and investment has lagged....
Novel Therapeutic and Trial Approaches for Lysosomal Storage Disorders with Polaryx’s Alex Yang — Episode 249
In episode 249 of the Xtalks Life Science Podcast, Alex Yang, JD, LLM, CEO of Polaryx, discusses the company’s mission to develop disease‑modifying small‑molecule therapies for rare pediatric lysosomal storage disorders. Yang leverages more than 25 years of experience across...
IBS Awareness Month 2026: The Hidden Realities of IBS and the IBS Treatment Market
April 2026 marks IBS Awareness Month, spotlighting a condition that affects roughly 10‑15% of the global population and often goes undiagnosed. The campaign emphasizes education, stigma reduction, and earlier detection to improve quality of life. Meanwhile, the global IBS treatment...
How Your Clinical Notes Impact Military Veterans’ Disability Benefits
Clinicians’ progress notes are now the primary medical evidence for Veterans Affairs (VA) disability claims, and incomplete documentation is causing a surge in delayed or denied benefits. Last year veterans filed a record number of claims, with roughly one‑third rejected...
Dispatch From Iran: 'How Will We Rebuild What We Have Lost?'
US and Israeli airstrikes have demolished more than 115,000 civilian structures across Iran, including over 750 schools, 300 healthcare centers, and 90,000 homes. The attacks have killed over 3,400 people, with at least 1,500 civilians among the dead, and injured...
Loargys (Pegzilarginase) Wins FDA Nod for Ultrarare Metabolic Disorder After Earlier Setbacks
The U.S. FDA granted accelerated approval to Loargys (pegzilarginase‑nbln) for treating arginase‑1 deficiency (ARG1‑D), an ultrarare metabolic disorder affecting roughly 250 Americans. Loargys, a recombinant human arginase‑1 enzyme, is the first therapy shown to lower plasma arginine levels, achieving about...
Nanotechnology Sensor Reads Creatinine in Seconds for Rapid Kidney Testing
Researchers at Tohoku University and City College of New York unveiled a nanotechnology‑based creatinine biosensor that reads concentrations from 1 to 300 mg/dL in about 35 seconds. The device uses a platinum‑nanoparticle polymer composite tuned near the percolation threshold, eliminating the...